BACKGROUND: Rhabdoid tumors are rare cancers of early childhood arising in the kidney, central nervous system and other organs. The majority are caused by somatic inactivating mutations or deletions affecting the tumor suppressor locus SMARCB1 [OMIM 601607]. Germ-line SMARCB1 inactivation has been reported in association with rhabdoid tumor, epitheloid sarcoma and familial schwannomatosis, underscoring the importance of accurate mutation screening to ascertain recurrence and transmission risks. We describe a rapid and sensitive diagnostic screening method, using high resolution melting (HRM), for detecting sequence variations in SMARCB1. METHODS: Amplicons, encompassing the nine coding exons of SMARCB1, flanking splice site sequences and th...
For relevant imatinib therapy against Philadelphia (Ph)-positive leukemias, it is essential to monit...
The identification of mutations and deletions in the SMARCB1 locus in chromosome band 22q11.2 in ped...
BACKGROUND: p53 is commonly inactivated by mutations in the DNA-binding domain in a wide range of ca...
Background : Rhabdoid tumors are rare cancers of early childhood arising in the kidney, central nerv...
Abstract The malignant rhabdoid tumor (RT) is one of the most aggressive childhood neoplasm. RTs ar...
SMARCB1 gene alterations were first described in highly malignant rhabdoid tumors of the kidney, bra...
Identification of somatic mutations in cancer is a major goal for understanding and monitoring the e...
In a subset of pediatric cancers, a germline cancer predisposition is highly suspected based on clin...
BACKGROUND: A diagnosis of malignant hyperthermia (MH) can be determined by performing an in vitro ...
Detection of mutations by DNA sequencing can be facilitated by scanning methods to identify amplicon...
Somatic mutations of the spliceosome machinery have been recently identified by whole genome analysi...
Abstract Background Germline inactivating mutations in BRCA1 and BRCA2 underlie a major proportion o...
Hotspot mutations of serine/arginine-rich splicing factor 2 (SRSF2) gene have been identified in a p...
Background. AT/RTs are rare aggressive brain tumours, mainly affecting young children. Most cases pr...
Abstract Background and Objective: High resolution melting (HRM) analysis is a technique to measur...
For relevant imatinib therapy against Philadelphia (Ph)-positive leukemias, it is essential to monit...
The identification of mutations and deletions in the SMARCB1 locus in chromosome band 22q11.2 in ped...
BACKGROUND: p53 is commonly inactivated by mutations in the DNA-binding domain in a wide range of ca...
Background : Rhabdoid tumors are rare cancers of early childhood arising in the kidney, central nerv...
Abstract The malignant rhabdoid tumor (RT) is one of the most aggressive childhood neoplasm. RTs ar...
SMARCB1 gene alterations were first described in highly malignant rhabdoid tumors of the kidney, bra...
Identification of somatic mutations in cancer is a major goal for understanding and monitoring the e...
In a subset of pediatric cancers, a germline cancer predisposition is highly suspected based on clin...
BACKGROUND: A diagnosis of malignant hyperthermia (MH) can be determined by performing an in vitro ...
Detection of mutations by DNA sequencing can be facilitated by scanning methods to identify amplicon...
Somatic mutations of the spliceosome machinery have been recently identified by whole genome analysi...
Abstract Background Germline inactivating mutations in BRCA1 and BRCA2 underlie a major proportion o...
Hotspot mutations of serine/arginine-rich splicing factor 2 (SRSF2) gene have been identified in a p...
Background. AT/RTs are rare aggressive brain tumours, mainly affecting young children. Most cases pr...
Abstract Background and Objective: High resolution melting (HRM) analysis is a technique to measur...
For relevant imatinib therapy against Philadelphia (Ph)-positive leukemias, it is essential to monit...
The identification of mutations and deletions in the SMARCB1 locus in chromosome band 22q11.2 in ped...
BACKGROUND: p53 is commonly inactivated by mutations in the DNA-binding domain in a wide range of ca...